Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 8/20 | 0.71 |
| ▸ | HTR7 | P34969 | 1/20 | 0.69 |
| ▸ | STS | P08842 | 1/20 | 0.56 |
| ▸ | RARB | P10826 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9625547 | 0.94 | HSD17B3 (0.72) | HSD17B3HTR7STSRARBL3MBTL1 | |
| SCHEMBL5130232 | 0.92 | HSD17B3 (0.73) | HSD17B3HTR7STSRARBL3MBTL1 | |
| SCHEMBL9625683 | 0.92 | HSD17B3 (0.73) | HSD17B3HTR7STSRARBL3MBTL1 | |
| SCHEMBL9625687 | 0.92 | HSD17B3 (0.73) | HSD17B3HTR7STSRARBL3MBTL1 | |
| SCHEMBL9625875 | 0.92 | HSD17B3 (0.73) | HSD17B3HTR7STSRARBL3MBTL1 | |
| SCHEMBL9626892 | 0.92 | HSD17B3 (0.73) | HSD17B3HTR7STSRARBL3MBTL1 | |
| SCHEMBL9626903 | 0.92 | HSD17B3 (0.73) | HSD17B3HTR7STSRARBL3MBTL1 | |
| SCHEMBL9440276 | 0.92 | HSD17B3 (0.73) | HSD17B3HTR7STSRARBL3MBTL1 | |
| SCHEMBL14522305 | 0.91 | HSD17B3 (0.83) | HSD17B3HTR7STSL3MBTL1HPGD | |
| SCHEMBL9346532 | 0.87 | HSD17B3 (0.67) | HSD17B3HTR7RARBL3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9885008-B2 | Photolabile pro-fragrances | HENKEL AG & CO. KGAA (DE) | 2018-02-06 | — | — | US | disclosed |
| US-20160186103-A1 | PHOTOLABILE PRO-FRAGRANCES | HENKEL AG & CO. KGAA | 2016-06-30 | — | — | US | disclosed |
| US-9312041-B2 | Photolabile pro-fragrances | HENKEL AG & CO. KGAA (DE) | 2016-04-12 | — | — | US | disclosed |
| US-20140110605-A1 | PHOTOLABILE PRO-FRAGRANCES | HENKEL AG & CO. KGAA (DE) | 2014-04-24 | — | — | US | disclosed |
| US-20070191420-A1 | Kinase inhibitors | DEVGEN NV | 2007-08-16 | — | — | US | disclosed |
| EP-1715862-A1 | KINASE INHIBITORS | Devgen NV (BE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005082367-A1 | KINASE INHIBITORS | DEVGEN NV (BE) | 2005-09-09 | — | — | WO | disclosed |
| EP-0733037-A1 | ARYL SUBSTITUTED AMINO ACIDS, CNS INFLUENCING AGENTS | UNIVERSITY OF BRISTOL (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995015941-A1 | ARYL SUBSTITUTED AMINO ACIDS, CNS INFLUENCING AGENTS | UNIVERSITY OF BRISTOL (GB) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160186103-A1 | PHOTOLABILE PRO-FRAGRANCES | CUTA, TRPA1, PIR | HSD17B3 4385/4885HTR7 521/4885STS 2328/4885 |
| US-20070191420-A1 | Kinase inhibitors | ROCK1, ROCK2, MAP3K20 | HSD17B3 2185/4885HTR7 4036/4885STS 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.